Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Subcutaneous vs Intravenous Daptomycin
NCT04434300Phase 1Completed
- Sponsor
- CHU Caen Normandie
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of daptomycin in bacterial infection (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Daptomycin dosage at 24 hours. Started Oct 2020; status: completed.
02
Drugs
daptomycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04434300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04434300.